PMID- 16353083
OWN - NLM
STAT- MEDLINE
DCOM- 20070614
LR  - 20220227
IS  - 1110-0362 (Print)
IS  - 1110-0362 (Linking)
VI  - 17
IP  - 1
DP  - 2005 Mar
TI  - Importance of serum IL-18 and RANTES as markers for breast carcinoma progression.
PG  - 51-5
AB  - BACKGROUND: Interleukin-18 (IL-18), a cytokine that plays an important role in 
      the T-cell-helper response, acts as an angiogenic factor and a tumor suppressor. 
      RANTES (regulated upon activation normal T-cells expressed and secreted) is a 
      member of the C-C chemokine family with chemoattractant activity for a variety of 
      cell types. High incidence and intensity of RANTES were noted in advanced breast 
      carcinoma. AIM OF THE STUDY: To correlate the levels of RANTES and IL-18 in serum 
      of breast cancer patients with bone or other organ metastasis compared to breast 
      cancer patients without metastasis and healthy controls and to estimate the role 
      of each of them as a prognostic marker for the progression of the disease. 
      PATIENTS AND METHODS: The study was conducted on 60 breast cancer patients (25 
      cases with no metastasis and 35 cases with metastasis) who were admitted to the 
      outpatient clinic of the NCI, Cairo University during the period from March 2004 
      to September 2004 and 30 apparently healthy controls who were volunteers at the 
      blood bank of the NCI, Cairo University. RESULTS: Showed that there was a 
      statistically significant difference between the level of IL-18 in breast cancer 
      patients without metastasis and the control group (p<0.05) while there was a 
      highly significant difference between the metastatic group and the control group 
      (p<0.001). There was a significant increase in IL-18 levels between metastatic 
      and non-metastatic cases (p<0.01). RANTES showed a significant increase in breast 
      cancer cases with no metastasis and the control group (p<0.05) and it showed a 
      highly significant increase in metastatic patients compared to controls 
      (p<0.001). There was no significant increase in the level of RANTES in metastatic 
      compared to non-metastatic patients (p>0.05). CONCLUSIONS: IL-18 is an important 
      non invasive marker suspecting metastasis. Even though RANTES levels were higher 
      in cancer patients compared to controls, its role in staging of breast cancer was 
      not clear in this study.
FAU - Eissa, Soheir A L
AU  - Eissa SA
AD  - Department of Clinical Pathology, National Cancer Institute, Cairo University, 
      Cairo.
FAU - Zaki, Samar A
AU  - Zaki SA
FAU - El-Maghraby, Shereen M
AU  - El-Maghraby SM
FAU - Kadry, Dalia Y
AU  - Kadry DY
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Egypt Natl Canc Inst
JT  - Journal of the Egyptian National Cancer Institute
JID - 9424566
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Chemokine CCL5)
RN  - 0 (Interleukin-18)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers, Tumor/*blood
MH  - Bone Neoplasms/*diagnosis/secondary
MH  - Breast Neoplasms/diagnosis/*pathology
MH  - Carcinoma/diagnosis/*secondary
MH  - Chemokine CCL5/*blood
MH  - Disease Progression
MH  - Female
MH  - Humans
MH  - Interleukin-18/*blood
MH  - Middle Aged
MH  - Neoplasm Metastasis
EDAT- 2005/12/15 09:00
MHDA- 2007/06/15 09:00
CRDT- 2005/12/15 09:00
PHST- 2005/12/15 09:00 [pubmed]
PHST- 2007/06/15 09:00 [medline]
PHST- 2005/12/15 09:00 [entrez]
PST - ppublish
SO  - J Egypt Natl Canc Inst. 2005 Mar;17(1):51-5.